何敏柯

一、基本情况

周三上午越秀门诊

二、教育及工作经历

2009年9月-2014年6月：中山大学临床医学专业本科，获医学学士学位；

2014年9月-2017年6月：中山大学肿瘤学专业型硕士，获医学硕士学位；

2018年9月-2021年6月：中山大学肿瘤学学术型博士，获医学博士学位；

2021年8月-2022年7月：中山大学肿瘤防治中心住院医师规范化培训；

2021年8月-2023年7月：中山大学肿瘤防治中心博士后；

2021年7月至今：中山大学肿瘤防治中心肝脏外科医师；

2023年12月至今：中山大学肿瘤防治中心肝脏外科副研究员。

三、主持科研项目

1. 国家自然科学基金委员会, 青年科学基金项目, 82203126, ABCA1调控肝癌TLR4/TGFβ通路介导肿瘤免疫逃逸的机制, 2023-01-01 至 2025-12-31, 30万元, 在研, 主持

2. 中山大学副研究员科研启动基金，90万元，在研，主持

3. 中国博士科学基金会, 2021年度中国博士后科学基金第3批特别资助（站前）, 2021TQ0383, RCAN2通 过STAT3通路调控肝癌细胞生物学功能及化疗耐药的机制研究, 2021-08 至 2023-08, 18万元, 结题, 主持

四、代表性论著

1. MinKe He; QiJiong Li; RuHai Zou; JingXian Shen; WanQiang Fang; GuoSheng Tan; YuanMin Zhou; XiaoPing Wu; Li Xu; Wei Wei; Yong Le; ZhongGuo Zhou; Ming Zhao; Ying Guo; RongPing Guo; MinShan Chen; Ming Shi; Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion, JAMA Oncology, 2019, 5(7): 953-960

2. Qi-Jiong Li; Min-Ke He（共一）; Huan-Wei Chen; Wan-Qiang Fang; Yuan-Min Zhou; Li Xu; Wei Wei; Yao-Jun Zhang; Ying Guo; Rong-Ping Guo; Min-Shan Chen; Ming Shi; Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial, J Clin Oncol, 2021, 40(2): 150- 160

3.MinKe He; YeXing Huang; Zefeng Du; ZhiCheng Lai; Hanyue Ouyang; JingXian Shen; DongSheng Wen; QiJiong Li; YaoJun Zhang; Wei Wei; MinShan Chen; Li Xu; Anna Kan; Ming Shi; Lenvatinib, toripalimab plus FOLFOX chemotherapy in hepatocellular carcinoma patients with extrahepatic metastasis: A biomolecular exploratory, phase II trial (LTSC), Clinical Cancer Research, 2023, 29(24): 5104-5115

4. Anna Kan; Shuang Liu; Minke He（共一）; Dongsheng Wen; Haijing Deng; Lichang Huang; Zhicheng Lai; Yexing Huang; Ming Shi; MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma, JHEP Rep, 2023, 6(1)

5. He Minke; Le Yong; Li Qijiong; Yu Zishan; Li Shaohua; Wei Wei; Guo Rongping; Shi Ming; Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study, Cancer Communications, 2017, 36(12): 704-711

6. Min-Ke He; Run-Bin Liang; Yang Zhao; Yu-Jie Xu; Huan-Wei Chen; Yuan-Min Zhou; Zhi-Cheng Lai; Li Xu; Wei Wei; Yao-Jun Zhang; Min-Shan Chen; Rong-Ping Guo; Qi-Jiong Li; Ming Shi ; Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma, Therapeutic Advances in Medical Oncology, 2021, 13(17588359211002720)

7. Min-Ke He; Chuan Peng; Yang Zhao; Run-Bin Liang; Zhi-Cheng Lai; Anna Kan; Qi-Jiong Li; Wei Wei; Yao-Jun Zhang; Min-Shan Chen; Rong-Ping Guo; Ming Shi ; Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis, Cancer Immunology, Immunotherapy, 2021, 70(11): 3207-3216

8. ZhiCheng Lai; MinKe He（共一）; XiaoYun Bu; YuJie Xu; YeXing Huang; DongSheng Wen; QiJiong Li; Li Xu; YaoJun Zhang; Wei Wei; MinShan Chen; Anna Kan; Ming Shi ; Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial, European Journal of Cancer, 2022, 174: 68- 77

9. ZhiCheng Lai; YeXing Huang; DongSheng Wen; XuanJia Lin; Anna Kan; QiJiong Li; Wei Wei; MinShan Chen; Li Xu; Minke He（共通讯）; Ming Shi ; One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma, BMC Medicine, 2022, 2(1): 415-415

10. Yu-Jie Xu, Zhi-Cheng Lai, Anna Kan, Hui Liu, Yu Huang, Yue-Yuan Lai, Jie-Feng Weng, Zhao-Feng Wu, Ming Shi, Wei-Li Gu, Shuai Zhan, Min-Ke He. TMB Signature-Related RCAN2 Promotes Apoptosis by Upregulating EHF/DR5 Pathway in Hepatocellular Carcinoma. Front Biosci (Landmark Ed). 2024;29(7):243.

更新时间：2025.02.28